Management of advanced thymoma presenting with myasthenia gravis in a resource-limited setting: A case report
https://doi.org/10.47895/amp.vi0.8074
- Author:
I Wayan Losen Adnyana
1
;
Dian Daniella
2
Author Information
1. Division of Haematology and Oncology Medic, Department of Internal Medicine, Faculty of Medicine, University of Udayana / Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia
2. Department of Internal Medicine, Faculty of Medicine, University of Udayana / Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia
- Publication Type:Case Reports
- Keywords:
Case report
- MeSH:
Thymoma;
Myasthenia Gravis;
Drug Therapy;
Thymectomy
- From:
Acta Medica Philippina
2024;58(Early Access 2024):1-6
- CountryPhilippines
- Language:English
-
Abstract:
Thymomas are rare tumours which generally account for only 0.2 – 1.5% of mediastinal tumours in adults. Around 40% of patients present with systemic symptoms such as motor weakness due to myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. Based on recent guidelines, management of advanced thymoma uses a multimodal approach, which is thymectomy followed by radiotherapy, but not all health care centers have radiotherapy facilities.
A 52-year-old woman presented with nasal voice and had difficulty swallowing food. Patient was diagnosed with myasthenia gravis (MG). CT scan with contrast of the thorax showed a heterogenous solid mass in anterior mediastinum. Histopathological examination showed thymoma type B2. Thymectomy followed by seven cycles of platinum-based chemotherapy were done on the patient. Evaluation afterward showed complete remission of thymoma. The patient’s motor weakness improved after the chemotherapy. Post-chemotherapy period was uneventful at six months on follow-up visit. The dosage of acetylcholinesterase inhibitor drug is reduced periodically due to improvement in motor weakness.
The case emphasizes how to manage an advanced thymoma with MG with limited therapeutic options, and the
importance of multidisciplinary management involving oncologists, surgeons, and neurologists.
- Full text:8074-Article Text-146557-1-10-20240221.pdf
